Dataset Information

Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein.

ABSTRACT: Until now, COVID-19 caused by SARS-CoV-2 is engulfing the worldwide and still ranging to date, continuing to threaten the public health. The main challenge facing COVID-19 epidemic is short of fast-response and high-efficiency methods to determine SARS-CoV-2 viral pathogens. Herein, a nanobody-based label-free photoelectrochemical (PEC) immunosensor has been fabricated for rapidly detecting SARS-CoV-2 spike protein. As a small-size and high-stability antibody, nanobody was directly and well immobilized with Au nanoparticles and TiO₂ spheres by the interaction. Au deposited TiO₂ nanomaterial possessed 8.5 times photoelectric performance in comparison with TiO₂ in the presence of electron donor owing to surface plasma resonance effect of Au. Based on the steric hindrance effect, this immunoassay platform realized the linear detection from 0.015 to 15000 pg mL^-1, and a limit of detection was low as 5 fg mL^-1. The label-free PEC immunoassay design provides a new idea for convenient, rapid, and efficient test of SARS-CoV-2 spike protein and broadens further application of nanobody as an identification agent to specific biomarkers.

SUBMITTER: Chen Y

PROVIDER: S-EPMC9062376 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein.

Chen Yun Y Duan Wei W Xu Li L Li Guanghui G Wan Yakun Y Li Henan H

Analytica chimica acta 20220503

Until now, COVID-19 caused by SARS-CoV-2 is engulfing the worldwide and still ranging to date, continuing to threaten the public health. The main challenge facing COVID-19 epidemic is short of fast-response and high-efficiency methods to determine SARS-CoV-2 viral pathogens. Herein, a nanobody-based label-free photoelectrochemical (PEC) immunosensor has been fabricated for rapidly detecting SARS-CoV-2 spike protein. As a small-size and high-stability antibody, nanobody was directly and well immo ...[more]

PMID: 35589224

Similar Datasets

Project description:Validation and standardization of accurate serological assays are crucial for the surveillance of the coronavirus disease 2019 (COVID-19) pandemic and population immunity. We describe the analytical and clinical performance of an in-house fluorescent multiplex immunoassay (FMIA) for simultaneous quantification of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein and spike glycoprotein. Furthermore, we calibrated IgG-FMIA against World Health Organization (WHO) International Standard and compared FMIA results to an in-house enzyme immunoassay (EIA) and a microneutralization test (MNT). We also compared the MNT results of two laboratories. IgG-FMIA displayed 100% specificity and sensitivity for samples collected 13 to 150 days post-onset of symptoms (DPO). For IgA- and IgM-FMIA, 100% specificity and sensitivity were obtained for a shorter time window (13 to 36 and 13 to 28 DPO for IgA- and IgM-FMIA, respectively). FMIA and EIA results displayed moderate to strong correlation, but FMIA was overall more specific and sensitive. IgG-FMIA identified 100% of samples with neutralizing antibodies (NAbs). Anti-spike IgG concentrations correlated strongly (ρ = 0.77 to 0.84, P < 2.2 × 10-16) with NAb titers, and the two laboratories' NAb titers displayed a very strong correlation (ρ = 0.95, P < 2.2 × 10-16). Our results indicate good correlation and concordance of antibody concentrations measured with different types of in-house SARS-CoV-2 antibody assays. Calibration against the WHO international standard did not, however, improve the comparability of FMIA and EIA results. IMPORTANCE SARS-CoV-2 serological assays with excellent clinical performance are essential for reliable estimation of the persistence of immunity after infection or vaccination. In this paper we present a thoroughly validated SARS-CoV-2 serological assay with excellent clinical performance and good comparability to neutralizing antibody titers. Neutralization tests are still considered the gold standard for SARS-CoV-2 serological assays, but our assay can identify samples with neutralizing antibodies with 100% sensitivity and 96% specificity without the need for laborious and slow biosafety level 3 (BSL-3) facility-requiring analyses.

Dataset Information

Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein.

Publications

Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets